In contrast, the 95% confidence interval (CI) indicated a significant enhancement in the levels of autoantibodies targeting claudin 5 and transglutaminase 6 in the mild COVID-19 group but a non-significant range between higher and lower autoantibody levels for the mild and moderate COVID-19 groups when compared to healthy controls. The gene discussed is CLDN5; the disease is COVID-19.